Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.
In this episode of Skinfluenced: The Skin Podcast, we break down the FDA’s latest approval of ZORYVE® (roflumilast) Cream 0.05%, marking a new topical treatment option for young children living with atopic dermatitis.
Join us as we discuss:
🌿 Clinical trial data showing safety and efficacy in patients aged 2–5 years
💊 How PDE-4 inhibition with roflumilast differs from current treatment options
🧴 What this means for real-world management of pediatric eczema
This exciting update highlights continued innovation in pediatric dermatology and expands therapeutic options for our youngest patients.
Link to Source(s):
Arcutis. FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.05 for the Treatment of Atopic Dermatitis in Children Ages 2 to 5. Published October 6, 2025. Accessed October 8, 2025. https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-atopic-dermatitis-in-children-ages-2-to-5/
Arcutis Biotherapeutics. FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.05 Treatment. Published October 6, 2025. Accessed October 8, 2025. https://investors.arcutis.com/news-releases/news-release-details/fda-approves-arcutis-zoryver-roflumilast-cream-005-treatment
HCPLive. FDA Approves Roflumilast (Zoryve) Cream 0.05 for Atopic Dermatitis in Children Aged 2-5 Years. Published October 6, 2025. Accessed October 8, 2025. https://www.hcplive.com/view/fda-approves-roflumilast-zoryve-cream-0-05-for-atopic-dermatitis-in-children-aged-2-5-years
HCPLive. Roflumilast Cream 0.05% Effective for Atopic Dermatitis in Patients Aged 2-5 Years. Published February 22, 2025. Accessed October 8, 2025. https://www.hcplive.com/view/roflumilast-cream-0-05-effective-atopic-dermatitis-patients-aged-2-5-years
HCPLive. Significance of Roflumilast Approval in Atopic Dermatitis Children — Lawrence Eichenfield, MD. Published October 8, 2025. Accessed October 8, 2025. https://www.hcplive.com/view/significance-roflumilast-approval-atopic-dermatitis-children-lawrence-eichenfield-md
HMP Global Learning Network / The Derm. FDA Alerts: FDA Approves Roflumilast Cream 0.05 Treatment for Atopic Dermatitis in Children. Published October 6, 2025. Accessed October 8, 2025. https://www.hmpgloballearningnetwork.com/site/thederm/fda-alerts/fda-approves-roflumilast-cream-005-treatment-atopic-dermatitis-children
The Derm Digest. U.S. FDA Approves Roflumilast Cream 0.05 for AD in Kids Aged 2 to 5. Published October 6, 2025. Accessed October 8, 2025. https://thedermdigest.com/u-s-fda-approves-roflumilast-cream-0-05-for-ad-in-kids-aged-2-to-5
Zoryve HCP. [Homepage]. Accessed October 8, 2025. https://www.zoryvehcp.com/
#AD #atopicdermatitis #Dermatology #SkinHealth #NewTreatments #FDAApproved #topicalTherapies #ClinicalGuidelines #FDAApproval #UTDDermatology #SkinScience #EvidenceBasedMedicine #ADManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast